Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polycystic Ovary Syndrome | 4 | 2011 | 26 | 1.270 |
Why?
|
| Metformin | 2 | 2011 | 64 | 0.740 |
Why?
|
| Caloric Restriction | 2 | 2011 | 29 | 0.490 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 121 | 0.380 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 152 | 0.350 |
Why?
|
| Phenotype | 1 | 2011 | 650 | 0.340 |
Why?
|
| Educational Measurement | 1 | 2006 | 80 | 0.280 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2006 | 75 | 0.280 |
Why?
|
| Clinical Competence | 1 | 2006 | 124 | 0.270 |
Why?
|
| Exercise | 1 | 2010 | 524 | 0.270 |
Why?
|
| Cultural Diversity | 1 | 2006 | 158 | 0.270 |
Why?
|
| Students, Medical | 1 | 2006 | 121 | 0.260 |
Why?
|
| Attitude of Health Personnel | 1 | 2006 | 186 | 0.260 |
Why?
|
| Myometrium | 2 | 2015 | 12 | 0.260 |
Why?
|
| Schools, Medical | 1 | 2006 | 192 | 0.250 |
Why?
|
| Vitamin D | 2 | 2013 | 176 | 0.200 |
Why?
|
| Double-Blind Method | 2 | 2011 | 269 | 0.190 |
Why?
|
| Testosterone | 2 | 2011 | 181 | 0.190 |
Why?
|
| Glucose Intolerance | 1 | 2018 | 42 | 0.170 |
Why?
|
| Female | 13 | 2018 | 19873 | 0.170 |
Why?
|
| Sleep Deprivation | 1 | 2018 | 23 | 0.170 |
Why?
|
| HIV Seropositivity | 2 | 2011 | 182 | 0.170 |
Why?
|
| Quality of Life | 2 | 2011 | 459 | 0.150 |
Why?
|
| Treatment Outcome | 2 | 2011 | 1349 | 0.150 |
Why?
|
| Pregnant Women | 2 | 2018 | 48 | 0.140 |
Why?
|
| Transcription Factor RelA | 1 | 2015 | 37 | 0.140 |
Why?
|
| Carcinogens, Environmental | 1 | 2015 | 34 | 0.130 |
Why?
|
| Adult | 7 | 2018 | 11034 | 0.130 |
Why?
|
| Histone Deacetylases | 1 | 2015 | 52 | 0.130 |
Why?
|
| Benzo(a)pyrene | 1 | 2015 | 122 | 0.130 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2015 | 155 | 0.120 |
Why?
|
| Pilot Projects | 2 | 2018 | 628 | 0.120 |
Why?
|
| Muscle Contraction | 1 | 2013 | 63 | 0.120 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2015 | 283 | 0.120 |
Why?
|
| Humans | 12 | 2018 | 34853 | 0.120 |
Why?
|
| Immunity, Maternally-Acquired | 2 | 2012 | 11 | 0.110 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 248 | 0.110 |
Why?
|
| Serotyping | 1 | 2012 | 36 | 0.110 |
Why?
|
| Streptococcus pneumoniae | 1 | 2012 | 28 | 0.110 |
Why?
|
| Pneumococcal Infections | 1 | 2012 | 27 | 0.110 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2013 | 137 | 0.110 |
Why?
|
| Fetal Blood | 1 | 2012 | 47 | 0.110 |
Why?
|
| Antibodies, Bacterial | 1 | 2012 | 107 | 0.100 |
Why?
|
| Chickenpox | 1 | 2011 | 6 | 0.100 |
Why?
|
| Herpesvirus 3, Human | 1 | 2011 | 12 | 0.100 |
Why?
|
| Pregnancy | 5 | 2018 | 1503 | 0.100 |
Why?
|
| Papillomavirus Infections | 1 | 2016 | 316 | 0.100 |
Why?
|
| HIV Seronegativity | 1 | 2011 | 38 | 0.100 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2011 | 99 | 0.100 |
Why?
|
| Placebo Effect | 1 | 2010 | 13 | 0.100 |
Why?
|
| Glycemic Index | 1 | 2010 | 8 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 142 | 0.100 |
Why?
|
| Diet, Reducing | 1 | 2010 | 22 | 0.100 |
Why?
|
| Ovulation | 1 | 2010 | 20 | 0.100 |
Why?
|
| NF-kappa B | 1 | 2013 | 306 | 0.100 |
Why?
|
| Exercise Therapy | 1 | 2011 | 64 | 0.100 |
Why?
|
| Patient Dropouts | 1 | 2010 | 26 | 0.100 |
Why?
|
| HIV Infections | 3 | 2016 | 2207 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2011 | 429 | 0.090 |
Why?
|
| Risk Factors | 3 | 2018 | 3414 | 0.090 |
Why?
|
| Measles | 1 | 2008 | 6 | 0.090 |
Why?
|
| Life Style | 1 | 2010 | 288 | 0.080 |
Why?
|
| Young Adult | 3 | 2018 | 4012 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2012 | 775 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2011 | 727 | 0.080 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2008 | 67 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2011 | 1056 | 0.080 |
Why?
|
| Prevalence | 4 | 2016 | 1425 | 0.080 |
Why?
|
| Time Factors | 1 | 2011 | 1681 | 0.070 |
Why?
|
| Adolescent | 2 | 2016 | 5035 | 0.060 |
Why?
|
| Obesity | 1 | 2012 | 965 | 0.060 |
Why?
|
| Tennessee | 2 | 2016 | 59 | 0.060 |
Why?
|
| Health Status Disparities | 1 | 2008 | 583 | 0.050 |
Why?
|
| United States | 1 | 2011 | 3894 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 628 | 0.050 |
Why?
|
| Cytokines | 2 | 2015 | 569 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2012 | 871 | 0.040 |
Why?
|
| Antibodies, Viral | 2 | 2011 | 252 | 0.040 |
Why?
|
| Incidence | 1 | 2018 | 882 | 0.030 |
Why?
|
| Rats, Long-Evans | 1 | 2015 | 86 | 0.030 |
Why?
|
| Biotransformation | 1 | 2015 | 65 | 0.030 |
Why?
|
| Random Allocation | 1 | 2015 | 139 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2015 | 197 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2015 | 149 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2015 | 212 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2016 | 125 | 0.030 |
Why?
|
| Premature Birth | 1 | 2015 | 71 | 0.030 |
Why?
|
| Receptors, Prostaglandin | 1 | 2013 | 10 | 0.030 |
Why?
|
| Receptors, Oxytocin | 1 | 2013 | 8 | 0.030 |
Why?
|
| I-kappa B Proteins | 1 | 2013 | 38 | 0.030 |
Why?
|
| Cytosol | 1 | 2013 | 85 | 0.030 |
Why?
|
| Connexin 43 | 1 | 2013 | 36 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2013 | 96 | 0.030 |
Why?
|
| Comorbidity | 1 | 2016 | 606 | 0.030 |
Why?
|
| Cyclooxygenase 2 | 1 | 2013 | 92 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2013 | 78 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 105 | 0.030 |
Why?
|
| Parathyroid Hormone | 1 | 2012 | 36 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 984 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2013 | 528 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 2012 | 129 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2013 | 834 | 0.030 |
Why?
|
| Vitamin D Deficiency | 1 | 2012 | 94 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2011 | 185 | 0.020 |
Why?
|
| HIV | 1 | 2011 | 97 | 0.020 |
Why?
|
| Adiposity | 1 | 2012 | 145 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2013 | 878 | 0.020 |
Why?
|
| Cell Line | 1 | 2013 | 1289 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 1152 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 1422 | 0.020 |
Why?
|
| Infant | 1 | 2011 | 1014 | 0.020 |
Why?
|
| Male | 1 | 2006 | 18870 | 0.020 |
Why?
|
| Animals | 1 | 2015 | 14307 | 0.010 |
Why?
|